Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;35(3):936-943.
doi: 10.1007/s13577-022-00689-2. Epub 2022 Mar 15.

Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma

Yooksil Sin  1 , Yuki Yoshimatsu  1 , Rei Noguchi  1 , Ryuto Tsuchiya  1 , Takuya Ono  1 , Taro Akiyama  1 , Shintaro Iwata  2 , Jun Sugaya  2 , Akihiko Yoshida  3 , Akira Kawai  2 , Tadashi Kondo  4
Affiliations

Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma

Yooksil Sin et al. Hum Cell. 2022 May.

Abstract

Dedifferentiated liposarcoma (DDLPS) is a highly aggressive subtype of liposarcoma that is morphologically defined as a transition from a well-differentiated lipomatous component to a non-lipogenic one. Curative therapy for DDLPS is complete resection, and the benefits of current systemic chemotherapy remain marginal. Although DDLPS is molecularly characterized by co-amplification of MDM2 and CDK4 (12q14-15) and detailed genomic analyses have been conducted by multiple research groups, the effects of molecular targeted drugs are marginal, and novel therapeutic modalities are required. Although patient-derived cell lines are pivotal for cancer research, no DDLPS cell lines are currently available from public cell repositories. Accordingly, in this study, we established a novel DDLPS cell line, NCC-DDLPS5-C1, using surgically resected tumor tissues from a patient with DDLPS. NCC-DDLPS5-C1 cells exhibited typical gene amplification, overexpression of MDM2 and CDK4, and other DNA copy number alterations. The NCC-DDLPS5-C1 cells were capable of rapid cell proliferation, aggressive invasion, and spheroid formation, but not tumor formation in mice. We reported the utility of NCC-DDLPS5-C1 cells for a drug-response assay to detect anticancer drugs that significantly attenuated cell proliferation. Thus, we concluded that the NCC-DDLPS5-C1 cell line could be a useful resource for the study of DDLPS. Considering the diversity of disease in terms of clinical outcomes, continuous efforts are required to develop more patient-derived cancer models with different clinical and pathological backgrounds.

Keywords: Dedifferentiated liposarcoma; Drug screening; Patient-derived cancer model; Patient-derived cell line; Sarcoma.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. WHO Classification of Tumours of Soft Tissue and Bone. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds) WHO Classification of Tumours, 4th edn. vol 5. ISBN-10: 9283245024, ISBN-13: 978-9283245025
    1. Tamaki T, Dong Y, Ohno Y, Sobue T, Nishimoto H, Shibata A. The burden of rare cancer in Japan: application of the RARECARE definition. Cancer Epidemiol. 2014;38:490–5. - DOI - PubMed
    1. Weiss SW, Rao VK. Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous site A follow-up study of 92 cases with analysis of the incidence of “dedifferentiation.” Am J Surg Pathol. 1992;16:1051–8. - DOI - PubMed
    1. Gahvari Z, Parkes A. Dedifferentiated liposarcoma: systemic therapy options. Curr Treat Options Oncol. 2020;21:15. - DOI - PubMed
    1. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–60. - DOI - PubMed

Substances